8-K: Theriva Biologics Announces 1-for-25 Reverse Stock Split to Maintain NYSE American Listing

Theriva Biologics has announced a 1-for-25 reverse stock split to meet the per share price requirements of the NYSE American.

Summary

• Theriva Biologics has approved a 1-for-25 reverse stock split of its common stock.
• The reverse stock split will be effective on August 26, 2024, at 12:01 a.m. Eastern Time.
• The number of outstanding shares will be reduced from 25,131,230 to approximately 1,005,249, subject to rounding.
• No fractional shares will be issued; instead, shareholders will receive the number of shares rounded up to the nearest whole share.
• The reverse stock split is intended to ensure the company meets the per share price requirements of the NYSE American.
• The company's trading symbol will remain TOVX, but the CUSIP number will change to 87164U 508.

Sentiment

Score: 3

Explanation: The announcement of a reverse stock split is generally viewed negatively by investors as it indicates a decline in the company's share price and is often a measure taken to avoid delisting. While the company is taking steps to maintain its listing, the underlying reason for the split is concerning.

Positives

• The reverse stock split will help Theriva Biologics maintain its listing on the NYSE American.
• Shareholders will not receive fractional shares, instead they will receive a whole share.

Negatives

• The reverse stock split will significantly reduce the number of outstanding shares.
• The reverse stock split is a sign that the company's share price has fallen below the NYSE American's minimum listing requirements.

Risks

• The reverse stock split may not have the desired effect on the company's share price.
• The company's ability to continue to enroll patients in clinical trials is subject to risks and uncertainties.
• Clinical trial results may not be consistent with prior results.
• The company may not be able to obtain regulatory approval for its product candidates.
• The company faces competition from other companies in the same industry.
• The company's ability to maintain license agreements and its patent estate is subject to risks.
• The company's ability to remain well financed is subject to risks.

Future Outlook

The company's future success depends on the success of its clinical trials, regulatory approvals, and market acceptance of its products. The company is also subject to risks related to competition, licensing agreements, and financing.

Management Comments

• The reverse stock split is being effected to ensure that the Company can meet the per share price requirements of the NYSE American.

Industry Context

Reverse stock splits are often used by companies to maintain listing compliance on exchanges when their share price falls below minimum requirements. This is a common practice in the biotech industry, where companies can experience significant volatility in their stock price due to the nature of drug development and clinical trials.

Comparison to Industry Standards

• Reverse stock splits are a common mechanism for companies facing delisting from major exchanges, particularly in the biotech sector where stock prices can be highly volatile.
• Other biotech companies that have recently undertaken reverse stock splits include XOMA Corporation (XOMA) and Agenus Inc. (AGEN), both of which faced similar challenges with maintaining their listing requirements.
• The 1-for-25 ratio is relatively high compared to some reverse splits, which can range from 1-for-2 to 1-for-10, indicating a significant drop in Theriva's share price.
• The fact that Theriva is rounding up fractional shares to the nearest whole share is a positive for shareholders, as some companies may choose to pay cash for fractional shares, which can be less favorable.

Stakeholder Impact

• Shareholders will see a reduction in the number of shares they own, but the value of their holdings should remain the same immediately after the split.
• The reverse stock split is intended to maintain the company's listing on the NYSE American, which is important for investor confidence.

Next Steps

• The company will file a certificate of change to its articles of incorporation with the Secretary of State of Nevada.
• The company's transfer agent will send instructions to stockholders of record regarding the exchange of their old certificates for new certificates, should they wish to do so.

Key Dates

Keywords

reverse stock split, NYSE American, stock listing, Theriva Biologics, TOVX, share price, common stock, CUSIP, clinical trials, oncolytic adenovirus, VCN-01, SYN-004, SYN-020